Objective: This study explored the association between long-term epilepsy surgery outcome and changes in depressive symptoms.
A standardized protocol to record history, neurologic evaluation, MRI, video-EEG monitoring, and neuropsychiatric assessments was administered. The Beck Depression Inventory (BDI) was validated for depression assessments in people with epilepsy, 8 including subjects from this cohort. 5 BDI scores between 0 and 11 were classified as not depressed, scores between 12 and 15 were classified as mild depression, and scores Ͼ15 were classified as moderate/severe depression. Assessments were conducted at baseline preoperatively and at 3, 12, 24, 48, and 60 months postoperatively. Epilepsy control was rated as excellent for subjects who were seizure-free (and no auras) for all 5 years, good if subjects were seizure-free for 2 consecutive years but not all 5, fair if subjects were seizure-free for 1 year but never 2 consecutive years, and poor if subjects never had a 1-year period of seizure freedom.
Standard protocol approvals, registrations, and patient consents. An institutional review board approved all procedures in the study.
Statistical methods. The change from baseline BDI score was calculated at each follow-up time point, and the distribution was examined. A mixed-model repeated-measures analysis (implemented with SAS PROC MIXED) was performed to compare change from baseline BDI score among different seizure control groups. The model included resection location, gender, age, race, education, time, and seizure control as fixed effects as well as random intercept and slope. Baseline depression and anxiety diagnosis, as established by the World Mental Health Composite International Diagnostic Interview (CIDI), were also further controlled in the model in the separate analysis. The significance level was set at 0.05.
RESULTS
Of the 373 adult subjects who were recruited and completed at least one BDI (table 1) , 164 (64.1%) were not depressed, 34 (13.3%) were mildly depressed, and 58 (22.7%) had moderate to severe depression at baseline, as classified by BDI score cutoffs. After 5 years, among 256 subjects who were reevaluated, 198 (77.3%) were not depressed, 20 (7.8%) were mildly depressed, and 38 (14.8%) were moderately to severely depressed (figure 1). Of the subjects with missing data at 5 years, 13 had moderate to severe depression, and 94 were not depressed at their last visit. There was no significant difference in baseline BDI score between completers and those with missing BDI data at 5 years (p ϭ 0.39). Among the 164 subjects who were not depressed at baseline, 10 subjects had BDI scores at the moderate to severe depression range at 5 years (figure 1). Of the 10 subjects who developed moderate to severe depressive symptoms at the 5 year follow-up, 4 met the criteria for an anxiety disorder within 1 year before their surgery and 2 had depressive disorders, as determined by the CIDI, within 1 year before their surgery; furthermore, 2 had excellent, 3 had good, 1 had fair, and 4 had poor seizure control after surgery.
Five years after surgery, differences in mean change from baseline BDI scores were demonstrated between excellent and poor seizure control ( p ϭ 0.006) as well as between excellent and fair seizure control ( p ϭ 0.02), respectively (figure 2; table e-1 on the Neurology ® Web site at www.neurology.org). Study participants with good seizure control had greater reductions in BDI scores (less depressive symptoms) than those with poor seizure control ( p ϭ 0.02) (figure 2). Seizure location (including laterality), age, race, and education were not associated with depression outcomes. Subjects with depressive disorder and anxiety disorders at baseline, as determined by the CIDI, had greater reductions in the change in BDI score during follow-up than people without depressive and anxiety disorders at baseline (figure e-1, table e-2). The association between seizure control and BDI was similar with or without controlling for baseline diagnosis.
DISCUSSION Whereas most study participants in this cohort had initial improvement in depressive symptoms after surgery, only subjects with good or excellent seizure control had sustained long-term improvement 5 years after surgery. In contrast to crosssectional studies showing no relationship between seizure frequency and depression score, 2 we found that good seizure control was associated with more improved depressive symptoms. Further, we previously found that subjects with excellent seizure con- trol have an improvement in quality of life (including the mental health component of the quality-of-life measure) compared with subjects with persistent seizures after surgery. 9 In contrast to previous studies, this study demonstrated that patients with good seizure control had depressive scores comparable to those of subjects who were seizure-free throughout the 5 years. Interestingly, even subjects with poorly controlled seizures demonstrated an initial drop in BDI score. The initial drop may be due to a placebo response postoperatively, a transient effect of surgery, a result of the additional care provided by being enrolled in a study, or partial improvement with seizure frequency. Conversely, 10 subjects who reported no depressive symptoms at baseline, reported moderate to severe depressive symptoms after 5 years. However, at least 2 of those patients had a history of depression, and 4 had comorbid anxiety disorders. Some of these patients may continue to have emotional lability due to limbic dysregulation.
Although the linear mixed-effects model we used demonstrates how BDI scores changed per subpopulation over time, it does not link the timing of seizure breakthrough to depressive symptoms. Our data cannot determine whether depressive symptoms are a part of a peri-ictal phenomenon or a psychological response to experiencing breakthrough seizures. Another limitation of the study is that access to and quality of mental health care including antidepressant medication use, cognitive behavioral therapy, or other therapeutic strategies shown to be efficacious for epilepsy and depression were not recorded systematically. In depression clinical trials as well as the clinical setting, as many as 70% of patients discontinue antidepressant medications within 1 year of treatment, 10 but we do not know the patterns of mental health care in this study cohort. Another limitation is that depression assessments were done by BDI score, which reflects state rather than trait characteristics, is based on self-reporting of symptoms, and may be systematically biased on persons with epilepsy because of overlap of the disorder with somatic symptoms and side effects of antiepileptic drug use. Whereas the CIDI was administered at baseline and at 2 years after surgery, it was not administered at 3, 4, and 5 years after surgery. Because psychotherapeutic and psychotropic management were not adequately monitored in this study, we may not draw conclusions on whether epilepsy surgery directly improves mood symptoms. However, subjects who achieved good seizure control after surgery also experienced long-term mood improvement. Those with only fair or poor outcomes after surgery did not, in the long term, appear to experience similar benefits. Further research is needed to explore the long-term temporal relationship between seizures and mood symptoms. Measurement of access to and quality of mental health care should be incorporated into epilepsy surgical outcomes studies.
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